Clinical Trials Offered

Below is a list of our currently enrolling studies at Metroplex Clinical Research Center as well as upcoming studies.  If you have any questions, please do not hesitate to give us a call at (214) 879-6737 or contact us using the CONTACT US form.

 
Search:
Indication:
 
* Click the plus sign ( + ) to see more information
IndicationsTrial IDTrial StatusTrial NameTrial TitleTrial CommentsClinicalTrials.gov ID
Anklyosing SpondylitisNovartis ASLeapEnrollingStudy estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitisStudy estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

http://www.novartisclinicaltrials.com

NCT03350815
Anklyosing SpondylitisPfizer A3921120EnrollingA Phase 3, Randomized, Double-blind, Placebo-controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)A Phase 3, Randomized, Double-blind, Placebo-controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS) NCT03502616
Giant Cell ArteritisSanofi 068EnrollingA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell ArteritisA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis NCT03600805
LupusACEA AC00582017-101EnrollingA Phase 1b Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients with Systemic Lupus Erythematosus (SLE)A Phase 1b Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients with Systemic Lupus Erythematosus (SLE)

For more information, Contact 214-404-0405

NCT03878303
LupusLilly I4V-MC-JAIAEnrollingA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus ErythematosusA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus NCT03616964
LupusResolve 132EnrollingA Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) NCT02660944
Osteoarthritis of the KneeCentrexion 303EnrollingThis is an open-label, single injection (per knee), 8-week study to evaluate the comfort and ease of use of 5 different treatment regimens, and to evaluate the efficacy and safety of a single intra-articular (IA) injection, in one or both knees, of 1.0 mg of CNTX-4975-05 in subjects with chronic, moderate-to-severe knee OA pain. Procedural pain associated with IA injection of the investigational product, CNTX-4975-05, will be controlled primarily through adjunct controlled joint cooling and secondarily by pre-medication with IA lidocaine.This is an open-label, single injection (per knee), 8-week study to evaluate the comfort and ease of use of 5 different treatment regimens, and to evaluate the efficacy and safety of a single intra-articular (IA) injection, in one or both knees, of 1.0 mg of CNTX-4975-05 in subjects with chronic, moderate-to-severe knee OA pain. Procedural pain associated with IA injection of the investigational product, CNTX-4975-05, will be controlled primarily through adjunct controlled joint cooling and secondarily by pre-medication with IA lidocaine. NCT03661996
Osteoarthritis of the Knee, Osteoarthritis of the HipRegeneron 1602EnrollingA Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled SyringeA Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled Syringe NCT03491904
Polymyalgia RheumaticaSanofi 160EnrollingA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica NCT03600818
Rheumatoid ArthritisAmgen 20150196EnrollingA Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid ArthritisA Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis

For more information please contact Recruitment 214.424.0405

NCT03156023
Rheumatoid ArthritisAmgen 592149EnrollingPhase 1b. To evaluate the safety and tolerability of subcutaneous (SC)dose administrations of AMG 592 in subjects with active RA. Phase 2a. To evaluate the efficacy of AMG 592 at week 12 as measured by the American College of Rheumatology 20% improvement criteria (ACR 20) in adult subjects with moderate to severe RA.Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC)dose administrations of AMG 592 in subjects with active RA. Phase 2a. To evaluate the efficacy of AMG 592 at week 12 as measured by the American College of Rheumatology 20% improvement criteria (ACR 20) in adult subjects with moderate to severe RA. NCT03410056
Rheumatoid ArthritisTarget RAEnrollingIn a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening)In a randomized controlled clinical trial, investigators will compare the effects on [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening) NCT02374021
Rheumatoid Arthritis, LupusPfizer C1001EnrollingA Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid ArthritisA Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis NCT03334851